(Total Views: 349)
Posted On: 09/04/2019 9:53:08 AM
Post# of 154778
That is an interesting interpretation of the mono investigational trial that has or will be concluding soon.
As far as 525 mg dose for mono pivotal trial, I believe they will not do a single dose or random dose, but use the Receptor Occupancy Test to determine optimal dose for each individual.
EDIT: This is still odd to thank trial patients (whether HIV, TNBC, etc) in a NASH IND PR without specifically stating who.
As far as 525 mg dose for mono pivotal trial, I believe they will not do a single dose or random dose, but use the Receptor Occupancy Test to determine optimal dose for each individual.
EDIT: This is still odd to thank trial patients (whether HIV, TNBC, etc) in a NASH IND PR without specifically stating who.
(1)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
